Department of Histopathology, Sullivan Nicolaides Pathology and Royal Brisbane and Women's Hospital Brisbane, Brisbane, Australia.
Mod Pathol. 2010 Jun;23(6):834-43. doi: 10.1038/modpathol.2010.59. Epub 2010 Mar 12.
Adenocarcinoma of the lower esophagus and esophagogastric junction is increasing in incidence in Western countries. A metaplasia (Barrett esophagus)-dysplasia-carcinoma sequence induced by gastroesophageal reflux disease is established. Two patterns of Barrett dysplasias have been described-adenomatous (type 1) and non-adenomatous (type 2 or foveolar/hyperplastic type). Interestingly, little is known about non-adenomatous dysplasia. Esophagogastrectomy cases from 41 patients with glandular dysplasia with and without associated invasive adenocarcinoma of the lower esophagus were evaluated for expression of MUC2, MUC5AC, CDX2, villin, Ki67 and p53. Results were correlated with sub-classification of the dysplasia into morphologic patterns of adenomatous vs foveolar vs hybrid type. In addition, clinicopathological parameters including the presence and extent of background intestinal metaplasia were also evaluated. Foveolar type dysplasia was present in 46% of the cases and thus, was more common than adenomatous type or hybrid type (both approximately 27%) dysplasia. Immunohistochemistry confirmed the histological stratification in all cases. Foveolar type dysplasia commonly expressed MUC5AC (P<0.12) but was consistently negative for markers of intestinal differentiation, MUC2, CDX2 and villin (all P<0.01). By contrast, adenomatous type dysplasia frequently displayed intestinal differentiation markers (all P<0.0001) Hybrid-type dysplasia was similar to adenomatous type dysplasia in showing expression of intestinal differentiation markers (P<0.01) and therefore could not be sustained as a separate category. In conclusion, our study provides evidence for a non intestinal pathway to neoplastic development in Barrett esophagus, that is, gastric metaplasia-foveolar dysplasia-adenocarcinoma.
西方国家下段食管和食管胃交界腺癌的发病率正在上升。胃食管反流病引起的化生(巴雷特食管)-异型增生-癌序列已被确立。已经描述了两种 Barrett 异型增生模式-腺瘤性(1 型)和非腺瘤性(2 型或小凹/增生型)。有趣的是,对于非腺瘤性异型增生知之甚少。对 41 例伴有或不伴有下段食管腺癌浸润的腺性发育不良的食管胃切除术病例进行了 MUC2、MUC5AC、CDX2、villin、Ki67 和 p53 的表达评估。结果与异型增生的形态学模式(腺瘤性与小凹性与混合性)进行了相关性分析。此外,还评估了包括背景肠上皮化生的存在和程度在内的临床病理参数。小凹型异型增生占 46%,因此比腺瘤型或混合型(均约 27%)异型增生更常见。免疫组织化学在所有病例中均证实了组织学分层。小凹型异型增生通常表达 MUC5AC(P<0.12),但始终为肠分化标志物 MUC2、CDX2 和 villin 阴性(均 P<0.01)。相比之下,腺瘤型异型增生常显示肠分化标志物(均 P<0.0001),混合型异型增生在显示肠分化标志物方面与腺瘤型异型增生相似(P<0.01),因此不能作为单独的类别。总之,我们的研究为 Barrett 食管中肿瘤发生的非肠途径提供了证据,即胃化生-小凹异型增生-腺癌。